Movetis was acquired by Shire in 2010 for €428 million. Movetis focused on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. It was created by a team of entrepreneurs led by Dirk Reyn as a spin-off from Johnson & Johnson. Its products address GI disorders, such as severe chronic constipation, ascites, pediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-esophageal reflux disease. Movetis brought to market Resolor, a drug for chronic constipation.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.